ACADIA PHARMACEUTICALS INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
ACADIA PHARMACEUTICALS INC. (ACAD) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $392.83 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $392.83M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $290.06M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $185.54M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $267.47M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations |
|---|---|
| 2026-06-30 | $392.83M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $290.06M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $185.54M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $267.47M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $263.11M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $226.47M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $328.36M 10-Q · filed 2026-08-05 |
| 2024-09-30 | $163.92M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $182.90M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $210.51M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $194.43M 10-K · filed 2026-02-26 |
| 2023-09-30 | $103.96M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $116.06M 10-Q · filed 2024-08-07 |
| 2023-03-31 | $296.67M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $120.62M 10-K · filed 2026-02-26 |
| 2022-09-30 | $160.61M 10-Q · filed 2023-11-03 |
| 2022-06-30 | $145.60M 10-Q · filed 2023-08-03 |
| 2022-03-31 | $210.69M 10-Q · filed 2023-05-08 |
| 2021-12-31 | $153.21M 10-K · filed 2025-02-27 |
| 2021-09-30 | $100.41M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $272.73M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $310.26M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $331.80M 10-K · filed 2024-02-28 |
| 2020-09-30 | $458.12M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $316.21M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $178.83M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $194.47M 10-K · filed 2023-02-28 |
| 2019-09-30 | $390.26M 10-Q · filed 2020-11-04 |
| 2019-06-30 | $79.22M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $102.34M 10-Q · filed 2020-05-08 |
| 2018-12-31 | $139.58M 10-K · filed 2022-03-01 |
| 2018-09-30 | $67.01M 10-Q · filed 2019-10-31 |
| 2018-06-30 | $77.29M 10-Q · filed 2019-08-01 |
| 2018-03-31 | $119.15M 10-Q · filed 2019-05-02 |
| 2017-12-31 | $71.89M 10-K · filed 2021-02-25 |
| 2017-09-30 | $115.09M 10-Q · filed 2018-11-06 |
| 2017-06-30 | $146.26M 10-Q · filed 2018-08-08 |
| 2016-12-31 | $166.00M 10-K · filed 2020-02-27 |
| 2015-12-31 | $102.51M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |